* SSEC -0.91%, CSI300 -0.92%
* Health care firms slump on generic COVID pill deal
* China anti-graft watchdog to probe platform monopolies
* China to cut SLF rates in latest easing move -sources
SHANGHAI, Jan 21 (Reuters) - Chinese shares fell on Friday
as technology firms slid following a watchdog's fresh vow to
crack down on corruption among internet platforms, while a
U.N.-backed deal to produce cheap versions of a COVID-19 pill
weighed on healthcare firms.
** At the close, the Shanghai Composite index was
down 0.91% at 3,522.57.
** The blue-chip CSI300 index was down 0.92%, with
its financial sector sub-index lower by 0.56%, the
real estate index down 0.97% and the healthcare
sub-index down 2.43%.
** Nearly 30 generic drugmakers in Asia, Africa and the
Middle East will make cheap versions of Merck & Co's
COVID-19 pill, under a landmark U.N.-backed deal to give poorer
nations wider access to a drug seen as a weapon in fighting the
** The CSI Info Tech index fell 1.48% after
China's anti-graft watchdog pledged to investigate and punish
any corrupt behaviour found behind internet platform monopolies
as part of a focus on "new challenges and new situations" in its
** Broad investor sentiment remains fragile amid signs of
slowing growth in the world's second-largest economy.
** In the latest indication of easing moves to combat a
slowing economy, sources told Reuters that China's central bank
will cut interest rates on its standing lending facility loans
for all tenors on Friday.
** The smaller Shenzhen index ended down 1.45% and
the start-up board ChiNext Composite index was weaker by
** Around the region, MSCI's Asia ex-Japan stock index
was weaker by 1.13%, while Japan's Nikkei index
closed down 0.9%.
** At 0700 GMT, the yuan was quoted at 6.3416 per
U.S. dollar unchanged from its late session close on Thursday.
(Reporting by Andrew Galbraith)